Digital Therapeutics for Management of Chronic Diseases

Year : 2026 | Volume : 15 | Issue : 02 | Page :
By

Gaurav N. Patil,

Akash S. Jain,

Divakar R. Patil,

Azam Z. Shaikh,

Sameer R. Shaikh,

Hitendra S. Chaudhari,

S. P. Pawar,

  1. Student, Department of Pharmacy, P.S.G.V.P. MANDAL’S COLLEGE OF PHARMACY, SHAHADA, Maharashtra, India
  2. Asssistant Professors, Department of Pharmacy, P.S.G.V.P. MANDAL’s COLLEGE OF PHARMACY, SHAHADA, Maharashtra, India
  3. Asssistant Professors, Department of Pharmacy, P.S.G.V.P. MANDAL’s COLLEGE OF PHARMACY, SHAHADA, Maharashtra, India
  4. Asssistant Professors, Department of Pharmacy, P.S.G.V.P. MANDAL’s COLLEGE OF PHARMACY, SHAHADA, Maharashtra, India
  5. Asssistant Professors, Department of Pharmacy, P.S.G.V.P. MANDAL’s COLLEGE OF PHARMACY, SHAHADA, Maharashtra, India
  6. Asssistant Professors, Department of Pharmacy, P.S.G.V.P. MANDAL’s COLLEGE OF PHARMACY, SHAHADA, Maharastra, India
  7. Asssistant Professors, Department of Pharmacy, P.S.G.V.P. MANDAL’s COLLEGE OF PHARMACY, SHAHADA, Maharastra, India

Abstract

Digital therapeutics (DTx) mark a major advancement in modern medicine, using advanced software technologies to deliver clinically validated treatments for various physical and mental health conditions. Unlike general wellness apps that focus on fitness or lifestyle tracking, DTx are evidence-based medical interventions developed through rigorous clinical research to ensure safety, efficacy, and measurable outcomes. Delivered via digital platforms such as smartphones, tablets, or specialized medical devices, DTx aim to prevent, manage, and treat diseases through personalized and data-driven care. The rapid progress of information and communication technologies (ICT) has accelerated digital healthcare innovation, as seen with Pear Therapeutics’ reset the first FDA-approved DTx in 2017 for substance use disorder. This milestone signaled the start of a new era in medicine, where digital treatments can complement or even replace traditional drug-based therapies. Chronic diseases like diabetes, cardiovascular disorders, and respiratory illnesses cause over 70% of global deaths, often due to poor lifestyle habits and aging populations. DTx offer continuous, personalized care through real-time monitoring, behavioral insights, and feedback, helping patients manage their conditions more effectively. Technologies such as augmented reality (AR) and virtual reality (VR) further enhance outcomes by improving adherence, reducing medical errors, and lowering hospitalization rates. Since the FDA’s first approval, the DTx market has expanded rapidly, with over 400 products now available or in development to address conditions from depression and insomnia to diabetes and hypertension. Their key advantages accessibility, affordability, and scalability make DTx a powerful alternative to traditional, in-person healthcare. By merging clinical science with digital innovation, digital therapeutics are reshaping the healthcare landscape, shifting it from reactive illness treatment toward proactive, preventive, and personalized care for long-term well-being.

Keywords: DTx , Technology , AI , Machine Learning , Chronic Diseases

[This article belongs to Research and Reviews : A Journal of Medical Science and Technology ]

How to cite this article: Gaurav N. Patil, Akash S. Jain, Divakar R. Patil, Azam Z. Shaikh, Sameer R. Shaikh, Hitendra S. Chaudhari, S. P. Pawar. Digital Therapeutics for Management of Chronic Diseases. Research and Reviews : A Journal of Medical Science and Technology. 2026; 15(02):-.
How to cite this URL: Gaurav N. Patil, Akash S. Jain, Divakar R. Patil, Azam Z. Shaikh, Sameer R. Shaikh, Hitendra S. Chaudhari, S. P. Pawar. Digital Therapeutics for Management of Chronic Diseases. Research and Reviews : A Journal of Medical Science and Technology. 2026; 15(02):-. Available from: https://journals.stmjournals.com/rrjomst/article=2026/view=253017

References

  1. Chung JY. Digital therapeutics and clinical pharmacology. Transl Clin Pharmacol. 2019;27(1):6-11. doi:10.12793/tcp.2019.27.1.6.
  2. Ju JH, Sim B, Lee J, Lee JY. Reimbursement of digital therapeutics: Future perspectives in Korea. Korean Circ J. 2022;52(4):265-279. doi:10.4070/kcj.2022.0014.
  3. Shah AM, Shah SV. Digital therapeutics—A new era in healthcare. Natl J Physiol Pharm Pharmacol. 2023;13(11):1-5.
  4. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7.
  5. Molina-Recio G, Molina-Luque R, Jiménez-García AM, Ventura-Puertos PE, Hernández-Reyes A, Romero-Saldaña M. Proposal for the design and evaluation of digital therapeutics based on virtual reality, augmented reality, and artificial intelligence. J Clin Med. 2020;9(8):2585. doi:10.3390/jcm9082585.
  6. Iribarren SJ, Cato K, Falzon L, Stone PW. What is the economic evidence for mHealth? A systematic review of economic evaluations of mobile health solutions. PLoS One. 2017;12(2):e0170581. doi:10.1371/journal.pone.0170581.
  7. Bashi N, Fatehi F, Mosadeghi-Nik M, Askari MS, Karunanithi M. Digital health interventions for chronic disease management: A systematic review of reviews. BMJ Open. 2020;10(4):e036220. doi:10.1136/bmjopen-2019-036220.
  8. Agbo CC, Mahmoud QH, Eklund JM. Blockchain technology in healthcare: A systematic review. Healthcare (Basel). 2019;7(2):56. doi:10.3390/healthcare7020056.
  9. Strudwick G. Predicting nurses’ use of healthcare technology using the Technology Acceptance Model: An integrative review. CIN Comput Inform Nurs. 2015;33(5):189-198. doi:10.1097/CIN.0000000000000142. (This is the verified publication corresponding to this title.)
  10. Herndon JH, Hwang R, Bozic KJ. Healthcare technology and technology assessment. Eur Spine J. 2007;16(9):1293-1302. doi:10.1007/s00586-007-0394-z.
  11. Al Kuwaiti A, Nazer K, Al-Reedy A, Al-Shehri S, Al-Muhanna A, Subbarayalu AV, et al. A review of the role of artificial intelligence in healthcare. J Pers Med. 2023;13(6):951. doi:10.3390/jpm13060951.
  12. Tilala MH, Chenchala PK, Choppadandi A, Kaur J, Naguri S, Saoji R, et al. Ethical considerations in the use of artificial intelligence and machine learning in health care: A comprehensive review. 2024;16(6):e62443. doi:10.7759/cureus.62443.
  13. Mirza M, Jabeen H, Fatima A. Artificial intelligence in digital therapeutics for optimized healthcare. J Pharma Insights Res. 2025;3(2):346-357. doi:10.69613/g5mbda64.
  14. Al Kuwaiti A, Nazer K, Al-Reedy A, Al-Shehri S, Al-Muhanna A, Subbarayalu AV, et al. A review of the role of artificial intelligence in healthcare. J Pers Med. 2023;13(6):951. doi:10.3390/jpm13060951.
  15. Dias D, Cunha JPS. Wearable health devices—Vital sign monitoring, systems and technologies. Sensors (Basel). 2018;18(8):2414. doi:10.3390/s18082414.
  16. Piwek L, Ellis DA, Andrews S, Joinson A. The rise of consumer health wearables: Promises and barriers. PLoS Med. 2016;13(2):e1001953. doi:10.1371/journal.pmed.1001953.
  17. Ramakrishnan P, Yan K, Balijepalli C, Druyts E. Digital therapeutics in diabetes management. J Diabetes Sci Technol. 2022;16(5):1165-1178. (Please verify page numbers against the final published version if required by your journal.)
  18. American Diabetes Association Professional Practice Committee. Standards of medical care in diabetes—2020. Clin Diabetes. 2020;38(1):10-38. doi:10.2337/cd20-as01.
  19. Jacksonville University School of Nursing. Digital technologies for diabetes distress [Internet]. Jacksonville (FL): Jacksonville University; [cited 2026 Aug 7]. Available from: https://www.jacksonvilleu.com/
  20. Bonoto BC, de Araújo VE, Godói IP, de Lemos LLP, Godman B, Bennie M, et al. Efficacy of mobile health applications in the self-management of diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2017;12(3):e0174854. doi:10.1371/journal.pone.0174854.
  21. Kario K, Harada N, Okura A. Digital therapeutics in hypertension: Evidence and perspectives. 2022;79(10):2148-2158. doi:10.1161/HYPERTENSIONAHA.122.19414.
  22. Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, et al. A multicenter clinical trial to assess the efficacy of digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. J Clin Hypertens (Greenwich). 2020;22(10):1713-1722. doi:10.1111/jch.13993.
  23. Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: The HERB-DH1 pivotal trial. Eur Heart J. 2021;42(40):4111-4122. doi:10.1093/eurheartj/ehab559.
  24. Gonzales S, Okusaga OO, Reuteman-Fowler JC, et al. A digital medicine system in people with serious mental illness: User experience and feasibility. JMIR Form Res. 2022;6:e34893.
  25. Torous J, Bucci S, Bell IH, Kessing LV, Faurholt-Jepsen M, Whelan P, et al. The growing field of digital psychiatry: Current evidence and the future of apps, social media, chatbots, and virtual reality. World Psychiatry. 2021;20(3):318-335. doi:10.1002/wps.20883.
  26. Wharton S, Astrup A, Endahl L, Lean MEJ, Lau DCW. Estimating the effect of digital therapeutics for obesity and weight management: A systematic review. Obes Rev. 2023;24(2):e13566.
  27. Lee H, Ahn H. A mobile health application for personalized weight management using three-dimensional body imaging: Systematic review. JMIR Mhealth Uhealth. 2020;8(4):e16252.
  28. Kang SG, Kang JM, Cho SJ, Ko KP, Lee YJ, Lee HJ. Cognitive behavioral therapy using a mobile application synchronizable with a wearable device for insomnia treatment: A pilot study. J Clin Sleep Med. 2017;13(4):633-640.
  29. Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. J Family Med Prim Care. 2020;9(5):2207-2213.
  30. Camacho M, Robertson M, Abdullatif J, Certal V, Capasso R, Kushida CA. Smartphone applications for snoring. J Laryngol Otol. 2015;129(10):974-979. doi:10.1017/S0022215115002236.
  31. Sullivan AN, Lachman ME. Behavior change with fitness technology in sedentary adults: A review of the evidence for increasing physical activity. Front Public Health. 2017;4:289. doi:10.3389/fpubh.2016.00289.
  32. Linares-Del Rey M, Vela-Desojo L, Cano-de-la-Cuerda R. Mobile phone applications in Parkinson’s disease: A systematic review. Neurologia (Engl Ed). 2019;34(1):38-54. doi:10.1016/j.nrl.2017.03.006.
  33. Katwa U, Rivera E. Asthma management in the era of smart devices and health applications. Indian J Pediatr. 2018;85(9):757-762. doi:10.1007/s12098-018-2667-4.
  34. Ologundudu L, Rayner DG, Oppenheimer J, et al. Digital inhalers for asthma management: A systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023;11(5):1458-1470.e6. doi:10.1016/j.jaip.2023.01.012.
  35. Chrystyn H, Saralaya D, Shenoy A, et al. Accuracy of inhalation parameters recorded by a digital multidose dry powder inhaler (Digihaler) in patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2022;35(3):166-177. doi:10.1089/jamp.2021.0034.
  36. Abidi SR, Rickards T, Abidi SSR. Digital therapeutics for chronic obstructive pulmonary disease self-management: Emerging evidence and implementation considerations. In: MEDINFO 2023: Proceedings of the 19th World Congress on Medical and Health Informatics. Amsterdam: IOS Press; 2023. p. 1021-1025. doi:10.3233/SHTI230356.
  37. Chan AHY, Pleasants RA, Dhand R, et al. Digital inhalers for chronic obstructive pulmonary disease: A review of clinical evidence and future directions. Pulm Ther. 2021;7(2):345-376. doi:10.1007/s41030-021-00158-7.
  38. Seheult JN, O’Connell P, Tee KC, Bholah T, O’Connor DJ, O’Donnell DM, et al. The impact of device design on aerosol delivery from dry powder inhalers: A review of in vitro and clinical evidence. Pharm Res. 2014;31(10):2735-2747. doi:10.1007/s11095-014-1382-4.
  39. McCarthy M, Schueler P. Digital technologies and therapeutics in Alzheimer’s disease: Current status and future directions. J Prev Alzheimers Dis. 2019;6(4):217-220. doi:10.14283/jpad.2019.34.
  40. Zhang Y, Zhang Y, Jiang Z, et al. Electroencephalography and functional near-infrared spectroscopy in Alzheimer’s disease diagnosis and therapy monitoring: A multimodal perspective. Front Neurosci. 2023;17:1269359. doi:10.3389/fnins.2023.1269359.
  41. Elfaki AO, Alotaibi M. Mobile health applications for Alzheimer disease and dementia care: Opportunities and challenges. 2018;4:32. doi:10.21037/mhealth.2018.08.05.
  42. Wang C, Lee C, Shin H, et al. Digital therapeutics: From bench to bedside. NPJ Digit Med. 2023;6:38. doi:10.1038/s41746-023-00777-0.
  43. Romagnoli A, Valentino F, Zovi A, Ferrara F, Minghetti P. Development of digital therapeutics: Regulatory, clinical and technological perspectives. J Pharm Innov. 2023;18(4):1275-1287. doi:10.1007/s12247-022-09679-7.
  44. National Institute for Health and Care Excellence (NICE). Evidence standards framework for digital health technologies. Updated March 2022. London: NICE; 2022.
  45. Yan K, Balijepalli C, Druyts E, et al. The impact of digital therapeutics on health technology assessment: A systematic review. Front Digit Health. 2021;3:667016. doi:10.3389/fdgth.2021.667016.
  46. Fürstenau D, Gersch M, Schreiter S. Digital therapeutics: A systematic review, conceptual framework, and future research agenda. Bus Inf Syst Eng. 2023;65(3):349-360. doi:10.1007/s12599-022-00773-0.
  47. Sverdlov O, van Dam J, Hannesdottir K, Thornton-Wells T. Digital therapeutics: An integral component of digital innovation in drug development. Clin Pharmacol Ther. 2018;104(1):72-80. doi:10.1002/cpt.1036.
  48. Colloud S, Metcalfe T, Askin S, et al. Regulatory perspectives on digital health technologies and digital therapeutics. NPJ Digit Med. 2023;6:56. doi:10.1038/s41746-023-00815-x.
  49. Rassi-Cruz M, Valente F, Caniza MV. Digital therapeutics: The need for regulation and evidence generation. Diabetol Metab Syndr. 2022;14:48. doi:10.1186/s13098-022-00815-4.
  50. Crisafulli S, Santoro E, Recchia G, Trifirò G. Digital therapeutics in Europe: Regulatory pathways and implementation challenges. Front Med (Lausanne). 2023;10:1205655. doi:10.3389/fmed.2023.1205655.
  51. Adams T, Connor M, Whittaker R. Protecting and advancing digital medicine infrastructure. NPJ Digit Med. 2019;2:97. doi:10.1038/s41746-019-0177-4.
  52. Golbus JR, Price WN, Nallamothu BK. Privacy, preservation, and the right to digital health data. 2020;141(8):613-615. doi:10.1161/CIRCULATIONAHA.119.044193.
  53. Lehne M, Sass J, Essenwanger A, Schepers J, Thun S. Why digital medicine depends on interoperability. NPJ Digit Med. 2019;2:79. doi:10.1038/s41746-019-0158-7.
  54. Zhang H, Cao Y, Jiang H, Wang Y, Li X, Chen Z, et al. The future of digital health: Emerging technologies and clinical translation. Clin Transl Allergy. 2025;15:e70020. doi:10.1002/clt2.70020.
  55. Maricich YA, Kvedar JC. Digital therapeutics: Opportunities and challenges for the future of healthcare. NPJ Digit Med. 2021;4:104. doi:10.1038/s41746-021-00467-2.
  56. Whitehead L, Talevski J, Fatehi F, Beauchamp A. Barriers and facilitators to the implementation of digital health interventions: A systematic review. J Med Internet Res. 2023;25:e42719. doi:10.2196/42719.
  57. Stoumpos AI, Kitsios F, Talias MA. Digital transformation in healthcare: Technology acceptance and its applications. Int J Environ Res Public Health. 2023;20(4):3407. doi:10.3390/ijerph20043407.
  58. Watson A, Chapman R, Shafai G, Maricich YA. FDA regulation of digital therapeutics: Current status and future directions. Front Digit Health. 2023;5:1086219. doi:10.3389/fdgth.2023.1086219.
  59. Huh KY, Oh J, Lee SH, Yu KS. Clinical evaluation of digital therapeutics: Present and future perspectives. Healthc Inform Res. 2022;28(3):188-197. doi:10.4258/hir.2022.28.3.188.
  60. Ramani VK, Suresh KP. Prevalence of hypertension and diabetes mellitus in India: A systematic review and meta-analysis. J Family Med Prim Care. 2020;9(7):3264-3271. doi:10.4103/jfmpc.jfmpc_488_20.
Regular Issue Subscription Review Article
Volume 15
Issue 02
Received 20/04/2026
Accepted 02/06/2026
Published 20/08/2026
Publication Time 122 Days

Login

My IP

PlumX Metrics